

TRADEMARK

Nizoral

(ketoconazole)

Did you know

that in seborrhoeic dermatitis
a dominant role is played by
Pityrosporum yeasts?

And did you know

that *Pityrosporum* is exceptional
sensitive to ketoconazole,
alias Nizoral?

If you do, you know why Nizoral cream is the right answer to seborrhoeic dermatitis

Apply twice daily until a few days after remission of symptoms.

Indications: Nizoral cream is indicated for topical application in the treatment of dermatophyte infections of the skin, as well as in the treatment of cutaneous candidosis and tinea (pityriasis) versicolor. Nizoral cream is also indicated for the treatment of seborrhoeic dermatitis, a skin condition related with the presence of *Pityrosporum ovale*. **Precautions:** Irritation may occur when Nizoral cream is used immediately after prolonged treatment with topical corticosteroids. Therefore, it is recommended to continue applying the topical corticosteroid in the mornings and to apply Nizoral cream in the evenings, and to subsequently and gradually withdraw the steroid therapy over a period of 2-3 weeks.



JANSSEN

PHARMACEUTICA


B-2340 Beerse, Belgium

world leader in antimycotic research

Full prescribing information
available on request.

© Janssen Pharmaceutica

Two new titles from the BMJ's series of books of general interest by medical writers



Portraits from Memory by Sir James Howie

One of the *BMJ*'s most popular series, Sir James Howie's *Portraits from Memory* is now published as a complete collection. For this Memoir Club edition the author has provided three new portraits, an introductory self portrait, and an appendix in which he comments on the points raised in the widespread correspondence that resulted from the portraits' publication.

Sir James Howie's distinguished career has included appointments as professor of bacteriology in the University of Glasgow, director of the Public Health Laboratory Service, president of the Royal College of Pathologists, and president of the British Medical Association. This book is not about himself, however, but about the memorable personalities he has known in microbiology and in military, hospital, and academic medicine. Essential reading for all students of human nature.


Price: Inland £14.95; Abroad £17.50; USA \$29.00. BMA members: Inland £13.95; Abroad £16.50; USA \$27.00.

A Natural History of Everyday Life: A biographical guide for would-be doctors of society by Lord Taylor of Harlow

As doctor, politician, and administrator the late Lord Taylor was a key figure in the formative years of some varied institutions: the National Health Service; Harlow New Town (playing an important part in its development and in its industrial health service); and the Memorial University of Newfoundland, of which he was the first president and vice-chancellor. He also laid the foundations of Medicare in Canada by his skilful negotiations to resolve the doctors' strike in Saskatchewan. In his lively and provocative memoirs Lord Taylor relates his "personal voyage" from childhood, through student days at St. Thomas's to his later career in public life, providing on the way innumerable pungent observations together with his views on the origins of some of society's ills—and their cures.

Price: Inland £19.95; Abroad £24.00; USA \$40.00


BMA members: Inland £18.95; Abroad £23.00; USA \$38.00.



ORDER FORM

BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE
or any leading medical bookseller.

Please send me the following books:



- ☐ **Portraits from Memory**
☐ **A Natural History of
Everyday Life**

Prices include postage, by air abroad

NAME.....
Please print name and address clearly

ADDRESS.....

.....

.....

☐ I enclose.....

BMA Membership No.

Please make cheques payable to **British Medical Journal** or
debit my credit card (please tick box)


☐ Access ☐ American Express ☐ Mastercard ☐ Visa

Card No.

Card expiry date

Signature.....

☐ Please send me a book catalogue.



Adalat® retard: antihypertensive with cardioprotective effect

ADALAT RETARD

Composition: 1 sustained release tablet of Adalat retard contains 20 mg nifedipine.
Indications: 1. Coronary heart disease: Chronic stable angina pectoris (exercise angina), angina pectoris following infarction (except in the first 8 days following an acute myocardial infarction). 2. Hypertension. **Contraindications:** Hypersensitivity to Adalat retard and the whole period of pregnancy. There are no findings on use during lactation. Caution should be exercised in the presence of pronounced low blood pressure (severe hypotension: systolic blood pressure < 90 mmHg). Cardiovascular shock. **Side-effects:** Side-effects generally occur at the start of therapy and are often of a slight and transient nature: facial flush, heat sensation, headache. In isolated cases particularly at higher doses: nausea, dizziness, tiredness, skin reactions, paraesthesia, hypotensive reaction, palpitations and increased pulse rate. Occasionally leg oedema due to dilatation of the blood vessels. **Extremely rare:** during long-term therapy, gingival hyperplasia which regresses completely once therapy is discontinued; chest pain (which may be angina pectoris-like pain) – where this occurs and a causal connection with Adalat is suspected, therapy should be discontinued. Caution should be exercised with dialysis patients with malignant hypertension and irreversible renal failure with hypovolaemia, since vasodilatation can result in a reduction in blood pressure. Treatment of hypertension with this drug requires regular medical supervision. Individuals may react differently to this drug and some patient's ability to drive and to operate machinery may

be impaired. This applies particularly at the start of treatment, when changing from one preparation to another and if alcohol is consumed. **Mode of action:** Adalat retard is a calcium antagonist and is classified as a coronary therapeutic agent/antihypertensive agent. **Dosage:** Treatment should be adapted to the individual as much as possible according to the severity of the disease and the patient's response to therapy. **Dosage guidelines for:** Coronary heart disease: Chronic stable angina pectoris (exercise angina), angina pectoris following infarction; hypertension: 2 x daily 1 sustained release tablet Adalat retard. In some cases it may be necessary to increase the dose further to 2 x 2 sustained release tablets (2 x 40 mg). If sufficient therapeutic success is not observed in angina pectoris patients after approximately 14 days of therapy, this treatment should be replaced by the fast-acting (10 mg) Adalat capsule where this is advised by the physician. The tablets should be swallowed whole with a small amount of liquid independently of meals. **Dosage interval:** 12 hours, but in any case not less than 4 hours. **Interactions with other drugs:** Adalat retard/antihypertensive agents: concomitant administration may enhance the antihypertensive effect of nifedipine. Adalat retard/beta receptor blockers: the patient must be monitored carefully during concomitant administration since severe hypotension may occur; development of heart failure has been reported occasionally. Adalat retard/cimetidine: possible enhancement of antihypertensive effect. **Note:** If a particularly rapid onset of action is required for the

treatment of spasms of the coronary vessels (coronary spasm: Prinzmetal's angina, angina at rest) and particularly marked clinical pictures or impending angina pectoris attacks or acute hypertensive crisis, the fast-acting (10 mg) Adalat capsules should be used. Once the situation has improved, an attempt may be made to transfer to Adalat retard tablets. The light-sensitive active substance in the sustained release tablet is protected from light both inside and outside the packaging; nonetheless the tablets should only be removed from the foil immediately before use and should not be broken. **Presentations:** Adalat retard: packs with 30, 50 and 100 sustained release tablets containing 20 mg nifedipine. Hospital packs.

Bayer AG, Leverkusen, West-Germany.

Co.-No.:

Bayer

